Find A Physician
Return to Blood and Bone Marrow Transplant Overview
More on Blood and Bone Marrow Transplant
Hospital News
Return to Blood and Bone Marrow Transplant Overview
More on Blood and Bone Marrow Transplant
- Clinical Trial for a Novel Multiple Myeloma Vaccine Begins at New York Weill Cornell Medical Center
- Dr. Selina Chen-Kiang Honored as Researcher of the Year by the Leukemia and Lymphoma Society
- Gleevec May Be Effective Against a Second Blood Disease, According to Study To Be Presented at Hematology Meeting
- Helping Parents Do the Right Thing: New Guidelines on Umbilical Cord Blood Banking
- Latest Findings Presented at Second International Symposium on Pediatric Non-Hodgkin's Lymphoma
- Multiple Myeloma Oral Therapy REVLIMID Approved by FDA
- New Anti-Leukemia Drug Significantly Improves Survival Even for Patients With Late-Stage Disease, Study Finds
- NewYork-Presbyterian Hospital and Columbia University Medical Center Physicians-Scientists Present Latest Cancer Findings at American Society of Hematology Meeting
- NewYork-Presbyterian Hospital Oncologists, from Columbia, Weill Cornell, Co-Lead World's Largest Lymphoma Forum for Patients
- Weill Cornell Physician-Scientists Present Latest Cancer and Blood Findings at American Society of Hematology (ASH) Meeting
Research and Clinical Trials
Return to Blood and Bone Marrow Transplant Overview
More on Blood and Bone Marrow Transplant
Health Library
Clinical Services
Return to Blood and Bone Marrow Transplant Overview
More on Blood and Bone Marrow Transplant
Blood and Bone Marrow Transplant
The Bone Marrow Transplant Program of NewYork-Presbyterian Hospital/Columbia University Medical Center and the Bone Marrow and Blood Stem Cell Transplant Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center serve patients from the greater New York area, surrounding states, and countries abroad, with long-term survivors now numbering in the hundreds. As pioneers for more than 30 years in the development of bone marrow transplantation, both autologous (using a patient's own cells) and allogeneic (donated cells), NewYork-Presbyterian Hospital continues as a distinguished leader in the field. Our physicians have been involved in the development of "mini-transplants," which permit patients who would have previously been denied bone marrow transplants because of frailty or age a chance at curative treatment.
NewYork-Presbyterian Cancer Centers continue their leadership role in bone marrow and stem cell transplantation. Both NewYork-Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell have bone marrow transplant programs to treat patients with diseases such as leukemias, lymphomas, aplastic anemia, immune deficiency disorders, and some solid tumor cancers. NewYork-Presbyterian/Weill Cornell is an approved transplant center for the National Marrow Donor Program (NMDP), the largest registry of unrelated donors (almost five million) in the world, and is involved in groundbreaking research that is benefiting patients and attracting large numbers of patient referrals worldwide. In addition, Morgan Stanley Children's Hospital of NewYork-Presbyterian is also an approved NMDP Unrelated Stem Cell Transplant Center.
Hospital News
- Clinical Trial for a Novel Multiple Myeloma Vaccine Begins at New York Weill Cornell Medical Center
- Dr. Selina Chen-Kiang Honored as Researcher of the Year by the Leukemia and Lymphoma Society
- Gleevec May Be Effective Against a Second Blood Disease, According to Study To Be Presented at Hematology Meeting More
